“Axitinib Affects Cell Viability and Migration of a Primary Foetal Lung Adenocarcinoma Culture”

A standardized laboratory and surgical method for in vitro culture isolation and expansion of primary human Tenon’s fibroblasts

(2012) Elena De Falco et al.   CELL AND TISSUE BANKING

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor

(2011) Naruyuki Kobayashi et al.   LUNG CANCER

Well-differentiated fetal adenocarcinoma: A very uncommon malignant lung tumor

(2011) H. El Ouazzani et al.   Revista Portuguesa de Pneumologia

Reciprocal control of cell proliferation and migration

(2010) Alina De Donatis et al.   Cell Communication and Signaling

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma

(2009) N. Schicher et al.   CLINICAL CANCER RESEARCH

EGFR Mutations are More Frequent in Well-Differentiated than in Poor-Differentiated Lung Adenocarcinomas

(2009) Yan Liu et al.   PATHOLOGY & ONCOLOGY RESEARCH

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

(2008) T. M. Chin et al.   CLINICAL CANCER RESEARCH

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH